Omeros
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies,...
Latest News
5 hours ago · marketbeat.com
Omeros Q3 Earnings Call HighlightsOmeros NASDAQ: OMER reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss.
6 hours ago · seekingalpha.com
Omeros Corporation (OMER) Q3 2026 Earnings Call TranscriptOmeros Corporation (OMER) Q3 2026 Earnings Call Transcript
7 hours ago · zacks.com
Omeros (OMER) Surpasses Q3 Earnings and Revenue EstimatesOmeros (OMER) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.19 per share a year ago.
6 days ago · businesswire.com
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please c.
1 month ago · benzinga.com
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program EndsOmeros Corporation (NASDAQ:OMER) shares are trading lower Friday after the company announced that the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA, following re-examination of its original negative opinion from June.
1 month ago · businesswire.com
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMASEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (.
2 months ago · benzinga.com
Omeros Transplant Drug Could Be Bigger than Expected, Says AnalystCantor Fitzgerald on Tuesday upgraded Omeros Corp (NASDAQ:OMER), citing a better-than-expected Yartemlea launch.
3 months ago · zacks.com
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 months ago · zacks.com
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
6 months ago · marketbeat.com
Omeros Q1 Earnings Call HighlightsOmeros NASDAQ: OMER reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove OMER